Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong’s Insilico Medicine, FT says

March 29 (Reuters) – Eli Lilly will sign ​a $2 ‌billion deal with Hong Kong-listed biotech Insilico ‌Medicine, ​which ⁠uses artificial intelligence ⁠for drug discovery, the Financial Times ​reported on Sunday.

Lilly ⁠will acquire ⁠exclusive rights ​to sell ​a GLP-1 drug for ‌diabetes from Insilico Medicine, the ⁠FT report said, citing sources familiar ⁠with ‌the ⁠matter.

Reuters could ​not ‌immediately verify ​the report.

(Reporting ⁠by Rishabh Jaiswal in Bengaluru. Editing by Mark ​Potter)